Skip to content
value.today

Argos Therapeutics Inc.

Total raised
$55 M
5 rounds on record
Latest round
$22 M
Aug 2013
First round on record
Sep 2010
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Argos Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2013$22 MNo. 5$10 to $50 million

Argos Therapeutics Inc.: Raise no. 5, Aug 2013

Investors in this round

25 investors had bought by the notice of Aug 27, 2013: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Argos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $60 M offered; $38 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Nicolette · Executive Officer
  • Douglas A. Plessinger · Executive Officer
  • Frederick M. Miesowicz · Executive Officer
  • Jeffrey D. Abbey · Executive Officer, Director
  • Lori A. Harrelson · Executive Officer
  • Andrei A. Petrov · Director
  • Brian R. Underdown · Director
  • David A. Gryska · Director
  • Hubert D. Birner · Director
  • Jean A. Lamarre · Director
  • Philip R. Tracy · Director
  • Sander D. van Deventer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William N. Wofford, Secretary. Source: SEC Form D, newest notice filed Aug 27, 2013. Read the notice at the SEC.

equity, optionsSEC
Aug 2012$16 MNo. 4$10 to $50 million

Argos Therapeutics Inc.: Raise no. 4, Aug 2012

Investors in this round

24 investors had bought by the notice of Sep 11, 2012: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Argos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Nicolette · Executive Officer
  • Douglas A. Plessinger · Executive Officer
  • Frederick M. Miesowicz · Executive Officer
  • Jeffrey D. Abbey · Executive Officer, Director
  • Lori A. Harrelson · Executive Officer
  • Brian R. Underdown · Director
  • David A. Gryska · Director
  • Hubert D. Birner · Director
  • Philip R. Tracy · Director
  • Sander D. van Deventer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William N. Wofford, Secretary. Source: SEC Form D, newest notice filed Sep 11, 2012. Read the notice at the SEC.

equity, optionsSEC
Apr 2012$9 MNo. 3$2 to $10 million

Argos Therapeutics Inc.: Raise no. 3, Apr 2012

Investors in this round

30 investors had bought by the notice of Apr 24, 2012: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Argos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $50 M offered; $41 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$4,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Nicolette · Executive Officer
  • Douglas A. Plessinger · Executive Officer
  • Frederick M. Miesowicz · Executive Officer
  • Jeffrey D. Abbey · Executive Officer, Director
  • Lori A. Harrelson · Executive Officer
  • B. Jefferson Clark · Director
  • Brian R. Underdown · Director
  • David A. Gryska · Director
  • Hubert D. Birner · Director
  • Monique A. Laliberte · Director
  • Philip R. Tracy · Director
  • Sander Jefferson van Deventer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William N. Wofford, Secretary. Source: SEC Form D, newest notice filed Apr 24, 2012. Read the notice at the SEC.

equitySEC
Jul 2011$4 MNo. 2$2 to $10 million

Argos Therapeutics Inc.: Raise no. 2, Jul 2011

Investors in this round

29 investors had bought by the notice of Jul 29, 2011: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Argos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Nicolette · Executive Officer
  • Frederick M. Miesowicz · Executive Officer
  • Jeffrey D. Abbey · Executive Officer, Director
  • B. Jefferson Clark · Director
  • Brian R. Underdown · Director
  • Hubert D. Birner · Director
  • Michel Jefferson Greco · Director
  • Monique A. Laliberte · Director
  • Philip R. Tracy · Director
  • Sander Jefferson van Deventer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William N. Wofford, Secretary. Source: SEC Form D, newest notice filed Jul 29, 2011. Read the notice at the SEC.

debt, optionsSEC
Sep 2010$5 MNo. 1$2 to $10 million

Argos Therapeutics Inc.: Raise no. 1, Sep 2010

Investors in this round

27 investors had bought by the notice of Sep 20, 2010: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 25 investors are named for Argos Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$750,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles A. Nicolette · Executive Officer
  • Frederick M. Miesowicz · Executive Officer
  • Jeffrey D. Abbey · Executive Officer, Director
  • B. Jefferson Clark · Director
  • Brian R. Underdown · Director
  • Hubert D. Birner · Director
  • Ines Jefferson Holzbaur · Director
  • Michel Jefferson Greco · Director
  • Philip R. Tracy · Director
  • Sander Jefferson van Deventer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey D. Abbey, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 20, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Argos Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2013).

    SEC Form D · Aug 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2013

That is all the official record says: Argos Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

25 named in official filings. Open an investor to see everything it has backed.

Investors in Argos Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Aurora Ventures II LLCVenture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
AV II Argos Enrichment, LLCOthernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Caisse de depot et placement du QuebecFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Charles A. NicolettePersonnot statednot statedHeld Series D and E preferred stock (Form 3, 2014)SEC Form 3
Forbion Co-Investment II Cooperatief U.A.Fund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Frederick MiesowiczPersonnot statednot statedHeld Series E preferred stock (Form 3, 2016)SEC Form 3
Green Cross Corp.Companynot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Harbinger Aurora QP Venture Fund LLCVenture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Harbinger Aurora Venture Fund LLCVenture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Intersouth Affiliates V LPFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Intersouth Partners IV LP /NCFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Intersouth Partners V, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
JAIC USSII No. 1, LLCOthernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Jeffrey D. AbbeyPersonnot statednot statedHeld Series C, D and E preferred stock, director (Form 3, 2014)SEC Form 3
LCC Legacy Holdings Inc.Companynot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lumira Capital I Limited PartnershipFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lumira Capital I Quebec Limited PartnershipFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Mizuho Capital No. 3 Limited PartnershipFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Morningside Venture Investments LtdVenture capitalnot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Pharmstandard International S.A.Companynot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Public Joint Stock Co PharmstandardOthernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Striker Asia Opportunities Fund CorpFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TFG USA, LLCOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TVM V Life Science Ventures Gmbh & Co KGVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TVM V Life Science Ventures Management GmbH & Co. KGVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Argos Therapeutics Inc.
NameRoleNamed in
Charles A. NicoletteExecutive officerAug 2013
Douglas A. PlessingerExecutive officerAug 2013
Frederick M. MiesowiczExecutive officerAug 2013
Jeffrey D. AbbeyExecutive officerAug 2013
Lori A. HarrelsonExecutive officerAug 2013
Andrei A. PetrovDirectorAug 2013
Brian R. UnderdownDirectorAug 2013
David A. GryskaDirectorAug 2013
Hubert D. BirnerDirectorAug 2013
Jean A. LamarreDirectorAug 2013
Jeffrey D. AbbeyDirectorAug 2013
Philip R. TracyDirectorAug 2013
Sander D. van DeventerDirectorAug 2013
B. Jefferson ClarkDirectorApr 2012
Monique A. LaliberteDirectorApr 2012
Sander Jefferson van DeventerDirectorApr 2012
Michel Jefferson GrecoDirectorJul 2011
Ines Jefferson HolzbaurDirectorSep 2010